Adjuvants

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Adjuvants, Health sciences, Health, Clinical trials, Economy of New York City, NASDAQ, Immunologic adjuvant, Vaccine

The stock options were granted on August 2, 2021 at an exercise price of $9.45 per share, which is equal to the closing price of Dynavax common stock on the date of grant.

Key Points: 
  • The stock options were granted on August 2, 2021 at an exercise price of $9.45 per share, which is equal to the closing price of Dynavax common stock on the date of grant.
  • The options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of a stock option agreement covering the grant and Dynavax' 2021 Inducement Award Plan, which was adopted January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

Retrieved on: 
Tuesday, July 27, 2021
Clinical medicine, Medicine, Cancer, Cancer treatments, Adjuvant therapy, Adjuvants, Analgesics, Health effects of tobacco, Chemotherapy, Lung cancer

The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Key Points: 
  • The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
  • To access the live webcast, go to the investor relations section on the Companys website, or by clicking here: http://public.viavid.com/index.php?id=145975 .
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage of care.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and predicts benefit from adjuvant chemotherapy.

Global Vaccine Adjuvants Market Opportunity Outlook to 2027: The Strategies Adopted by Key Players - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
Health, Pharmaceutical, Medical specialties, Immunology, Health care, Medicine, Adjuvants, Immunologic adjuvant, Vaccine, Clinical trials, Polyclonal antibodies

High toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are some restraining factors which are expected to hamper the global vaccine adjuvants market growth.

Key Points: 
  • High toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are some restraining factors which are expected to hamper the global vaccine adjuvants market growth.
  • On the basis of type, the global vaccine adjuvants market is segmented into a Pathogen, Adjuvant Emulsion, Combination, Particulate, and Others.
  • The particulate type is expected to hold the largest market share in vaccine adjuvants market.
  • All these factors are expected to contribute the global vaccine adjuvants market growth over the forecast period.

Lumeda Announces Appointment of Jason Pesterfield to Board of Directors

Retrieved on: 
Tuesday, July 20, 2021
Health sciences, Medicine, Clinical medicine, Cancer treatments, Adjuvants, Pulmonology, Photodynamic therapy, Adjuvant therapy, Surgical oncology, Therapy

ROCKY HILL, Conn., July 20, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc. , a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors.

Key Points: 
  • ROCKY HILL, Conn., July 20, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc. , a medical technology company advancing Photodynamic Therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced the appointment of Jason Pesterfield to its board of directors.
  • "We are excited to have Jason join our board of directors to bring his deep experience in lung cancer surgery and global connections to thoracic surgeons and interventional pulmonologist," said Lumeda CEO, Sandy Zinke.
  • "Jason has significant expertise in developing innovative commercialization strategies to launch new medical technologies in the lung cancer space.
  • "I am excited to be joining the talented Lumeda team to help them introduce this important adjuvant therapy for treating lung cancer," said Pesterfield.

Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Retrieved on: 
Monday, July 19, 2021
Clinical medicine, Cancer, Medicine, Cancer treatments, Oncology, Surgical oncology, Adjuvant therapy, Adjuvants, Analgesics, Ovarian cancer, Neoadjuvant therapy, Debulking

The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV ovarian cancer.

Key Points: 
  • The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV ovarian cancer.
  • NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy.
  • Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of chemotherapy to treat any residual tumor.
  • The Company also announced that more than 50% of the projected 110 patients have been enrolled in the OVATION 2 Study.

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

Retrieved on: 
Monday, July 19, 2021
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Adjuvants, CRM197, Health sciences, Medical specialties, Vaccine, Health care, the Pelican Expression Technology™, Ligand Pharmaceuticals, THE PELICAN EXPRESSION TECHNOLOGY™, LIGAND PHARMACEUTICALS

VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing Ligands CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology platform.

Key Points: 
  • VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing Ligands CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology platform.
  • Under the terms of the licensing agreement with Merck, Ligand earned a $2 million milestone payment upon FDA approval of VAXNEUVANCE and is entitled to a low-single-digit royalty on net product sales.
  • Merck plans to submit a supplemental regulatory licensure application with the FDA later this year for the use of VAXNEUVANCE in children.
  • We are delighted to see Mercks progress with VAXNEUVANCE along with the FDA approval of another Pelican Expression Technology-enabled medical advancement, said John Higgins, CEO of Ligand.

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 2, 2021
Medical specialties, Adjuvants, Health sciences, Health, COVID-19 vaccines, Clinical trials, Immunologic adjuvant, Immunology, Vaccine, VLA2001

The stock options were granted on July 1, 2021 at an exercise price of $10.23 per share, which is equal to the closing price of Dynavax common stock on the date of grant.

Key Points: 
  • The stock options were granted on July 1, 2021 at an exercise price of $10.23 per share, which is equal to the closing price of Dynavax common stock on the date of grant.
  • The options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of a stock option agreement covering the grant and Dynavax' 2021 Inducement Award Plan, which was adopted January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, June 30, 2021
Vaccines, Medical specialties, Medicine, Clinical trials, COVID-19 vaccines, Adjuvants, SCB-2019, Science and technology in China, Immunology, COVID-19 vaccine, Immunologic adjuvant, Hepatitis B vaccine

Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.

Key Points: 
  • Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.
  • Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, June 30, 2021
Vaccines, Medical specialties, Medicine, Clinical trials, COVID-19 vaccines, Adjuvants, SCB-2019, Science and technology in China, Immunology, COVID-19 vaccine, Immunologic adjuvant, Hepatitis B vaccine

Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.

Key Points: 
  • Ryan Spencer, Chief Executive Officer of Dynavax commented, "Dynavax is excited for the opportunity to expand our partnership with Clover into an important commercial supply agreement to provide significant amounts of CpG 1018 for combatting the ongoing pandemic.
  • Clover's COVID-19 vaccine candidate is the combination of SCB-2019 and two adjuvants, Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.

Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, June 29, 2021
Adjuvants, Health sciences, Health, Medical specialties, Immunologic adjuvant, Strike price, Option, VLA2001

The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The option is subject to the terms and conditions of a stock option agreement covering the grant and Dynavax's 2021 Inducement Award Plan, which was adopted on January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.